



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/699,517		
		Filing Date	October 31, 2003		
		First Named Inventor	Schenk, Dale B.		
		Art Unit	1649		
Sheet	1	of	13	Examiner Name	Steven H. Standley
				Attorney Docket Number	015270-008920US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	1	US-7,138,255	11-21-2006	Vodyanoy et al.	
	2	US-2006/0259986	11-16-2006	Chilcote et al.	
	181	US-7,060,464	06-13-2006	Kim	
	3	US-2006/0058233	03-16-2006	Schenk et al.	
	4	US-2005/0255113	11-17-2005	Huston et al.	
	5	US-2005/0203010	09-15-2005	Kim	
	6	US-2005/0196818	09-08-2005	Chilcote et al.	
	7	US-2005/0198694	09-08-2005	Chilcote et al.	
	8	US-2005/0176078	08-11-2005	Allsop et al.	
	9	US-6,923,964	08-02-2005	Schenk	
	10	US-6,890,535	05-10-2005	Schenk	
	11	US-6,866,850	03-15-2005	Schenk	
	12	US-6,866,849	03-15-2005	Schenk	
	182	US-6,858,704	02-22-2005	Kim	
	13	US-2005/0037013	02-17-2005	Schenk et al.	
	14	US-6,787,144	09-07-2004	Schenk	
	15	US-6,787,143	09-07-2004	Schenk	
	16	US-6,787,140	09-07-2004	Schenk	
	17	US-6,787,139	09-07-2004	Schenk	
	18	US-6,787,138	09-07-2004	Schenk	
	19	US-6,780,971	08-24-2004	Wolozin et al.	
	20	US-2004/0146521	07-29-2004	Schenk et al.	
	21	US-2004/0137523	07-15-2004	Vodyanoy et al.	
	22	US-2004/0136993	07-15-2004	Schenk et al.	
	23	US-6,761,888	07-13-2004	Schenk	
	24	US-6,743,427	06-01-2004	Schenk	
	25	US-6,710,226	03-23-2004	Schenk	
	27	US-2003/0086938	05-08-2003	Jensen et al.	
	28	US-6,504,080	01-07-2003	Van Der Putten P.H.	
	29	US-2002/0094335	07-18-2002	Chalifour et al.	
Examiner Signature				Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/699,517
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Steven H. Standley
Sheet	2	of	13	Attorney Docket Number	015270-008920US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	31	US-2002/0187157	12-12-2002	Jensen et al.	
	32	US-2002/0160394 A1	10-31-2002	Wu	
	33	US-2002/0151464	10-17-2002	Wolozin et al.	
	219	US-5,753,624	05-19-1998	McMichael	
	37	US-5,589,154	12-31-1996	Anderson	
	38	US-5,576,184	11-19-1996	Better et al.	
	39	US-4,883,666	11-28-1989	Sabel et al	
U.S. PATENT APPLICATIONS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	214	US-11/894,772	08-20-2007	Schenk et al.	
	215	US-11/894,744	08-20-2007	Schenk et al.	
	216	US-11/894,605	08-20-2007	Schenk et al.	
	217	US-11/842,054	08-20-2007	Schenk et al.	
	218	US-11/841,996	08-20-2007	Schenk et al.	
	41	US-11/697,646	04-06-2007	Schenk et al.	
	40	US-11/710,248	02-23-2007	Schenk et al.	
	42	US-11/660,015	02-09-2007	Schenk et al.	
	43	US-10/850,570	05-19-2004	Chilcote et al.	
	44	US-60/518,140	11-08-2003	Chilcote et al.	
	45	US-60/471,929	05-19-2003	Chilcote et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	46	EP	0 613 007	A2	08-31-1994			<input type="checkbox"/>
	47	WO	07/021255	A1	02-22-2007	Chilcote et al.		<input type="checkbox"/>
	48	WO	07/012061	A2	01-25-2007	Schenk et al.		<input type="checkbox"/>
	49	WO	06/045037	A2	04-27-2006	Chilcote et al.		<input type="checkbox"/>
	50	WO	06/045037	A3	04-27-2006	Chilcote et al.		<input type="checkbox"/>
	51	WO	06/020581	A2 corrected version	02-23-2006	Schenk et al.		<input type="checkbox"/>
	52	WO	06/020581	A3	02-23-2006	Schenk et al.		<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/699,517
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Steven H. Standley
Sheet	3	of	13	Attorney Docket Number	015270-008920US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	53	WO	05/013889	A3 corrected version	02-17-2005	Chilcote et al.		<input type="checkbox"/>
	54	WO	05/047860	A2	05-26-2005	Chilcote et al.		<input type="checkbox"/>
	55	WO	05/047860	A3	05-26-2005	Chilcote et al.		<input type="checkbox"/>
	56	WO	04/041067	A2	05-21-2004	Schenk et al.		<input type="checkbox"/>
	57	WO	04/041067	A3	05-21-2004	Schenk et al.		<input type="checkbox"/>
	58	WO	04/009625	A2	01-29-2004	El-Agnaf et al.		<input type="checkbox"/>
	59	WO	04/009625	A3	01-29-2004	El-Agnaf et al.		<input type="checkbox"/>
	220	WO	03/045128	A2	06-05-2003	New York University		<input type="checkbox"/>
	221	WO	03/045128	A3	06-05-2003	New York University		<input type="checkbox"/>
	183	WO	01/053457	A2	07-26-2001	University of Connecticut Health Center		<input type="checkbox"/>
	184	WO	01/053457	A3	07-26-2001	University of Connecticut Health Center		<input type="checkbox"/>
	186	WO	01/06989	A3	02-01-2001	Abgenix, Inc.		<input type="checkbox"/>
	61	WO	00/72880	A3	12-07-2000	Schenk et al.		<input type="checkbox"/>
	63	WO	00/072876	A3	12-07-2000	Schenk		<input type="checkbox"/>
	64	WO	00/18917	A2 corrected version	04-06-2000	Amgen Inc.		<input type="checkbox"/>
	65	WO	00/18917	A3 corrected version	04-06-2000	Amgen Inc.		<input type="checkbox"/>
	66	WO	99/060024	A1 corrected version	11-25-1999	Solomon et al.		<input type="checkbox"/>
	67	WO	99/050300	A1	10-07-1999	Trojanowski et al.		<input type="checkbox"/>
	68	WO	99/040191	A1	08-05-1999	Shimizu et al.		Abst. only
	69	WO	99/027944	A1 corrected version	06-10-1999	Schenk		<input type="checkbox"/>
	71	WO	99/006545	A2 corrected version	02-11-1999	Max Plank Institute		<input type="checkbox"/>
	72	WO	99/006545	A3 corrected version	02-11-1999	Max Plank Institute		<input type="checkbox"/>
	73	WO	95/006407	A1	03-09-1995	Masliah		<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/699,517
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Steven H. Standley
Sheet	4	of	13	Attorney Docket Number	015270-008920US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	75	ABBAS et al., <u>Cellular and Molecular Immunology</u> , 522-523 (Elsevier Saunders) (5th Ed. Updated Ed., 2005).	<input type="checkbox"/>	
	76	BALES et al., "Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A β antibody," <u>J. Clin. Invest.</u> , 116(3):825-832 (2006).	<input type="checkbox"/>	
	187	BARD et al., "Peripherally administered antibodies against amyloid β -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <u>Nature Medicine</u> , 6(8):916-919 (2000).	<input type="checkbox"/>	
	77	BENNETT et al., "Degradation of α -Synuclein by Proteasome," <u>J. Biol. Chem.</u> , 274(48):33855-33858 (1999).	<input type="checkbox"/>	
	78	BROOKS et al., "Synuclein proteins and Alzheimer's disease," <u>Trends Neurosci.</u> , 17(10):404-405 (1994).	<input type="checkbox"/>	
	212	CHANG et al., "Adjuvant activity of incomplete Freund's adjuvant," <u>Advanced Drug Delivery Reviews</u> , 32:173-186 (1998).	<input type="checkbox"/>	
	80	CHEN et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V \rightarrow F transgenic mice," <u>Progress in Brain Research</u> , 117:327-337 (1998).	<input type="checkbox"/>	
	81	CLAYTON et al., "Synucleins in Synaptic Plasticity and Neurodegenerative Disorders," <u>J. Neurosci. Res.</u> , 58:120-129 (1999).	<input type="checkbox"/>	
	82	CLAYTON et al., "The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration, and disease," <u>Trends Neurosci.</u> , 21(6):249-254 (1998).	<input type="checkbox"/>	
	83	CLELAND et al., "Isomerization and Formulation Stability of the Vaccine Adjuvant QS-21," <u>J. of Pharm Sci.</u> , 85(1): 22-28 (1996).	<input type="checkbox"/>	
	85	CROWTHER et al., "Synthetic filaments assembled from C-terminally truncated α -synuclein," <u>FEBS Letters</u> , 436:309-312 (1998).	<input type="checkbox"/>	
Examiner Signature				Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/699,517
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Steven H. Standley
Sheet	5	of	13	Attorney Docket Number	015270-008920US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	86	DE LUSTIG et al., "Peripheral markers and diagnostic criteria in Alzheimer's disease: Critical evaluations," <u>Rev. in Neurosci.</u> , 5:213-225 (1994).	<input type="checkbox"/>	
	87	DEMATTO et al., "Peripheral Anti A β Antibody Alters CNS And Plasma A β Clearance and Decreases Brain A β Burden in a Mouse Model of Alzheimer's Disease," published online before print July 3, 2001 at 10.1073/pnas.151261398; <u>PNAS</u> , 98(15):8850-8855 (2001).	<input type="checkbox"/>	
	88	Dictionary.com definition of "prophylactic", pages 1-3 downloaded from internet 10/12/05.	<input type="checkbox"/>	
	89	Dictionary entry for "prophylactic", <u>Webster's New World Dictionary of American English</u> , 3rd College Edition, New York, page 1078 (1988).	<input type="checkbox"/>	
	90	DI MONTE et al., "Environmental Factors in Parkinson's Disease," <u>Neurotoxicology</u> , 23: 487-502 (2002).	<input type="checkbox"/>	
	191	DIXON, C. et al., "Alpha-Synuclein Targets the Plasma Membrane via the Secretory Pathway and Induces Toxicity in Yeast," <u>Genetics</u> , 2005 May;170(1):47-59. Epub 2005 March 2.	<input type="checkbox"/>	
	178	EL-AGNAF et al., "α-Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma," <u>FASEB J.</u> , 17(3):1945-1947 (2003).	<input type="checkbox"/>	
	91	EL-AGNAF et al., "α-Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma," <u>FASEB J. express article</u> 10.1096/fj.03-0098fje, Published online August 15, 2003.	<input type="checkbox"/>	
	94	ELIEZER, D. et al., "Conformational Properties of Alpha-Synuclein in its Free and Lipid-associated States," <u>Journal of Molecular Biology</u> , 307(4):1061-1073 (2001).	<input type="checkbox"/>	
	95	ELLIS et al., "α-Synuclein is Phosphorylated by Members of the Src Family of Protein-tyrosine Kinases," <u>J. Biol. Chem.</u> , 276(6):3879-3884 (2001).	<input type="checkbox"/>	
	96	EMADI, S. et al., "Inhibiting Aggregation of Alpha-Synuclein with Human Single Chain Antibody Fragments," <u>Biochemistry</u> , 43(10):2871-2878 (2004).	<input type="checkbox"/>	
Examiner Signature				Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/699,517
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Steven H. Standley
Sheet	6	of	13	Attorney Docket Number	015270-008920US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	98	EP 04776059.0 European Supplementary Search Report completed 06/13/2006.	<input type="checkbox"/>	
	99	FARRER, M.J., "Genetics of Parkinson disease: Paradigm shifts and future prospects," <u>Nat. Rev. Genet.</u> , 7:306-318 (2006).	<input type="checkbox"/>	
	104	FRIEDLAND et al., "'Development of an anti-A β monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," <u>Mol. Neurology</u> , 9:107-113 (1994).	<input type="checkbox"/>	
	192	GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with A β ₁₋₄₂ ," <u>Annals of the New York Academy of Science</u> , 920:274-284 (2000).	<input type="checkbox"/>	
	193	GARZON, J. et al., "Transport of CSF antibodies to G-Alpha subunits across neural membranes requires binding to the target protein and protein kinase C activity," <u>Molecular Brain Research</u> , 65(2):151-166 (1999).	<input type="checkbox"/>	
	106	GIASSON et al., "Mutant and Wild Type Human α -Synucleins Assemble into Elongated Filaments with Distinct Morphologies <i>in Vitro</i> ," <u>J. Biol. Chem.</u> , 274(12):7619-7622 (1999).	<input type="checkbox"/>	
	107	GOLDSBY et al., "Vaccines," Chapter 18 from <i>Immunology, 4th Edition</i> , W.H. Freeman and Company, New York, pages 449-465 (2000).	<input type="checkbox"/>	
	108	GOLDSTEINS et al., "Exposure of cryptic epitopes on transthyretin only in amypoid and in amyloidogenic mutants," <u>PNAS</u> , 96:3108-3113 (1999).	<input type="checkbox"/>	
	110	HAMBURGER, A.W. et al., "Isolation and characterization of monoclonal antibodies reactive with endothelial cells," <u>Tissue & Cell</u> , 17(4): 451-459 (1985).	<input type="checkbox"/>	
	111	HANSEN et al., "Chapter 14: Neurobiology of Disorders with Lewy Bodies," <u>Functional Neurobiology of Aging</u> , (Hof and Mobbs, Eds.) 173-182 (2001).	<input type="checkbox"/>	
	213	HARLOW et al., eds., <i>Antibodies, A Laboratory Manual</i> , Cold Spring Harbor Laboratory page 98 (1988).	<input type="checkbox"/>	
Examiner Signature				Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/699,517
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Steven H. Standley
Sheet	7	of	13	Attorney Docket Number	015270-008920US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	112	HARTMAN et al., "Treatment with an Amyloid- β Antibody Ameliorates Plaque Load, Learning Deficits, and Hippocampal Long-Term Potentiation in a Mouse Model of Alzheimer's Disease," <u>Journal of Neuroscience</u> , 25:6213-6220 (2005).	<input type="checkbox"/>	
	195	HSAIO, K., "From prion diseases to Alzheimer's disease," <u>J. Neural. Transm. Suppl.</u> 49:135-144 (1997).	<input type="checkbox"/>	
	113	HOOPER et al., <u>Cellular Peptidases in Immune Functions and Diseases 2</u> , (Langer and Ansorge, Eds., Plenum Publishers) 379-390 (2000).	<input type="checkbox"/>	
	114	HOYER, W. et al., "Dependence of alpha-Synuclein Aggregate Morphology on Solution Conditions," <u>J. Mol. Biol.</u> , 322:383-393 (2002).	<input type="checkbox"/>	
	115	IRIZARRY, M.C. "Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α -synuclein immunoreactivity," <u>J. Neuropathol. Exp. Neurol.</u> , 57(4): 334-337 (1998).	<input type="checkbox"/>	
	179	IWAI, "Properties of NACP/alpha-synuclein and its role in Alzheimer's disease," <u>Molecular Basis of Disease</u> , 1502(1): 95-109 (2000).	<input type="checkbox"/>	
	209	IWAI et al., "The Precursor Protein of Non-A β Component of Alzheimer's Disease Amyloid Is a Presynaptic Protein of the Central Nervous System," <u>Neuron</u> , 14:467-475 (1995).	<input type="checkbox"/>	
	116	IWATSUBO, T. et al., "Purification and Characterization of Lewy Bodies from the Brains of Patients with Diffuse Lewy Body Disease," <u>Am J Pathol.</u> , 148(5):1517-1529 (1996).	<input type="checkbox"/>	
	117	JAKES et al., "Epitope mapping of LB509, a monoclonal antibody directed against human α -synuclein," <u>Neurosci. Ltrs.</u> , 269:13-16 (1999).	<input type="checkbox"/>	
	120	KIM, T. D. et al., "Structural and Functional Implications of C-Terminal Regions of α -Synuclein," <u>Biochemistry</u> , 41:13782-13790 (2002).	<input type="checkbox"/>	
	121	KIM, T.D. et al., "Structural Changes in α -Synuclein Affect its Chaperone-like Activity in Vitro," <u>Protein Science</u> , 9:2489-2496 (2000).	<input type="checkbox"/>	
Examiner Signature				Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/699,517	
			Filing Date	October 31, 2003	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Steven H. Standley	
Sheet	8	of	13	Attorney Docket Number	015270-008920US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	122	KOTZBAUER et al., "Lewy Body Pathology in Alzheimer's Disease," <u>Journal of Molecular Neuroscience</u> , 17(2): 225-232 (2001).	<input type="checkbox"/>	
	198	KUBY, J., eds., <u>Immunology</u> , pp. 92-97 and 110 (W.H. Freeman & Co., New York) (3rd Edition, 1997).	<input type="checkbox"/>	
	123	KUBY J., eds., <u>Immunology</u> , pp. 92-97 and 131 (W.H. Freeman & Co., New York) (3rd Edition, 1997).	<input type="checkbox"/>	
	124	KUBY J., eds., <u>Immunology</u> , pp. 156-158 (W.H. Freeman & Co., New York) (3rd Edition, 1997).	<input type="checkbox"/>	
	199	LANSBURY JR., P. T., "Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease," <u>Proc Natl Acad Sci</u> , 96(7): 3342-3344 (1999).	<input type="checkbox"/>	
	125	LEE et al., "Formation and Removal of α -Synuclein Aggregates in Cells Exposed to Mitochondrial Inhibitors," <u>J. Biol. Chem.</u> , 277(7):5411-5417 (2002).	<input type="checkbox"/>	
	126	LEE et al., "Human α -synuclein-harboring familial Parkinson's disease-linked Ala-53 \rightarrow Thr mutation causes neurodegenerative disease with α -synuclein aggregation in transgenic mice," <u>PNAS</u> , 99:8968-8973 (2002).	<input type="checkbox"/>	
	200	LEMERE, C. A. et al., Amyloid-Beta Immunization in Alzheimer's Disease Transgenic Mouse Models and Wildtype Mice," <u>Neurochem Res.</u> , 28(7):1017-27.2003).	<input type="checkbox"/>	
	128	LIPPA et al., "Antibodies to α -Synuclein Detect Lewy Bodies in Many Down's Syndrome Brains with Alzheimer's Disease," <u>Ann. Neurol.</u> , 45:353-357 (1999).	<input type="checkbox"/>	
	129	LUCKING et al., "Alpha-synuclein and Parkinson's disease," <u>Cell. Mol. Life Sci.</u> , 57:1894-1908 (2000).	<input type="checkbox"/>	
	201	LUTHI-CARTER, R., "Progress towards a Vaccine for Huntington's Disease," <u>Mol Ther.</u> , 7(5, Pt 1):569-70 (2003).	<input type="checkbox"/>	
Examiner Signature				Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/699,517
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Steven H. Standley
Sheet	9	of	13	Attorney Docket Number	015270-008920US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	130	MA et al., "A-synuclein aggregation and neurodegenerative diseases," <u>Journal of Alzheimer's Disease</u> , 5(2):139-148 (2003).	<input type="checkbox"/>	
	131	MASLIAH et al., "Effects of α -Synuclein Immunization in a Mouse Model of Parkinson's Disease," <u>Neuron</u> , 46: 857-868 (2005).	<input type="checkbox"/>	
	203	MCLEAN, et al., "Membrane Association and Protein Conformation of Alpha-Synuclein in Intact Neurons," <u>J Biol Chem</u> , 275(12):8812-6 (2000).	<input type="checkbox"/>	
	133	Merriam-Webster online medical dictionary, entry for "cure", accessed September 5, 2006.	<input type="checkbox"/>	
	134	MISHIZEN-EBERZ et al., "Distinct cleavage patterns of normal and pathologic forms of α -synuclein by calpain I <i>in vitro</i> ," <u>J. Neurochemistry</u> , 86:836-847 (2003).	<input type="checkbox"/>	
	204	MORGAN, et al., "A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," <u>Nature</u> , 408(6815):982-5 (2000).	<input type="checkbox"/>	
	135	MUNCH et al., "Potential neurotoxic inflammatory response to A β vaccination in humans," <u>J. Neural Transm.</u> , 109:1081-1087 (2002).	<input type="checkbox"/>	
	136	OKOCHI, M. "Constitutive Phosphorylation of the Parkinson's Disease Associated α -Synuclein," <u>J. Biol. Chem.</u> , 275(1): 390-397 (2000).	<input type="checkbox"/>	
	137	PALHA et al., "Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy," <u>J. Mol. Med.</u> , 78:703-707 (2001).	<input type="checkbox"/>	
	138	PCT/US05/37875 International Preliminary Report on Patentability Chapter 1 issued 04/24/2007 with Written Opinion	<input type="checkbox"/>	
	139	PCT/US05/28166 International Preliminary Report on Patentability Chapter 1 issued 02/13/2007 with Written Opinion	<input type="checkbox"/>	
Examiner Signature				Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/699,517	
			Filing Date	October 31, 2003	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Steven H. Standley	
Sheet	10	of	13	Attorney Docket Number	015270-008920US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	140	PCT/US04/37444 International Preliminary Report on Patentability Chapter 1 issued 06/19/2007 with Written Opinion	<input type="checkbox"/>	
	141	PCT/US04/015836 International Preliminary Report on Patentability Chapter 1 issued 11/25/2005 with Written Opinion	<input type="checkbox"/>	
	142	PCT/US00/015239 International Preliminary Examination Report dated 08/13/2001	<input type="checkbox"/>	
	144	PRIMAVERA et al., "Brain Accumulation of Amyloid- β in Non-Alzheimer Neurodegeneration," <u>Journal of Alzheimer's Disease</u> , 1:183-193 (1999).	<input type="checkbox"/>	
	145	QUE et al., "Effect of Carrier Selection on Immunogenicity of Protein Conjugate Vaccines against Plasmodium falciparum Circumsporozoites," <u>Infection and Immunity</u> , 56(10): 2645-2649 (1988).	<input type="checkbox"/>	
	147	SCHENK, D., "Amyloid- β immunotherapy for Alzheimer's disease: the end of the beginning," <u>Nature Reviews</u> , 3:824-828 (2002).	<input type="checkbox"/>	
	149	SIGURDSSON et al., "Immunization Delays the Onset of Prion Disease in Mice," <u>American Journal of Pathology</u> , 161:13-17 (2002).	<input type="checkbox"/>	
	150	SIGURDSSON et al., "Anti-prion antibodies for prophylaxis following prion exposure in mice," <u>Neurosciences Letters</u> , 336:185-187 (2003).	<input type="checkbox"/>	
	151	SIPE, "Amyloidosis," <u>Annu. Rev. Biochem.</u> , 61:947-975 (1992).	<input type="checkbox"/>	
	152	SKIPPER et al., "Parkinson's Genetics: molecular Insights for the New Millennium," <u>Neurotoxicology</u> , 23: 503-514 (2002).	<input type="checkbox"/>	
	155	SMALL et al., "Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease," <u>PNAS</u> , 97(11):6037-6042 (2000).	<input type="checkbox"/>	
Examiner Signature				Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/699,517	
			Filing Date	October 31, 2003	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Steven H. Standley	
Sheet	11	of	13	Attorney Docket Number	015270-008920US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	156	SOLOMON et al., "Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β -amyloid peptide," <u>PNAS</u> , 93:452-455 (1996).	<input type="checkbox"/>	
	157	SOLOMON, B., "Immunological approaches as therapy for Alzheimer's disease," <u>Expert Opin. Biol. Ther.</u> , 2(8):907-917 (2002).	<input type="checkbox"/>	
	159	STEIN et al., "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways," <u>The Journal of Neuroscience</u> , 22(17):7380-7388 (2002).	<input type="checkbox"/>	
	160	SU et al., "Intravascular infusions of soluble β -amyloid compromise the blood-brain barrier, activate CNS Glial cells and induce peripheral hemorrhage," <u>Brain Research</u> , 818:105-107 (1999).	<input type="checkbox"/>	
	161	TAKAHASHI, M. "Phosphorylation of α -synuclein characteristic of synucleinopathy lesions is recapitulated in α -synuclein transgenic Drosophila," <u>Neuroscience Letters</u> , 336: 155-158 (2003).	<input type="checkbox"/>	
	180	TAKEDA et al., "Abnormal Distribution of the Non-A β Component of Alzheimer's Disease Amyloid Precursor/alpha-synuclein in Lewy Body Disease as Revealed by Proteinase K and Fromic Acid Pretreatment," <u>Laboratory Investigation</u> , 79(9):1169-1177 (1998).	<input type="checkbox"/>	
	162	TAKEDA, A. et al., "C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders," <u>Acta Neuropathol</u> , 99:296-304 (2000).	<input type="checkbox"/>	
	163	TAL et al., "Complete Freund's Adjuvant Immunization Prolongs Survival in Experimental Prion Disease in Mice," <u>Journal of Neuroscience Research</u> , 71:286-290 (2003).	<input type="checkbox"/>	
	164	TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," <u>European J. Pharmacology</u> , 352:135-142 (1998).	<input type="checkbox"/>	
	165	TENNENT et al., "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis," <u>PNAS</u> , 92:4299-4303 (1995).	<input type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/699,517
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Steven H. Standley
Sheet	12	of	13	Attorney Docket Number	015270-008920US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	166	TSIM, K.W. et al., "Monoclonal antibodies specific for the different subunits of asymmetric acetylcholinesterase from chick muscle," <u>J. Neurochem.</u> , 51(1):95-104 (1988).	<input type="checkbox"/>	
	207	UBOL et al., "Roles of Immunoglobulin Valency and the Heavy-Chain Constant Domain in Antibody-Mediated Downregulation of Sindbis Virus Replication in Persistently Infected Neurons," <u>J Virol.</u> , 1995 March; 69(3): 1990-1993.	<input type="checkbox"/>	
	167	VICKERS, J.C., "A vaccine against Alzheimer's disease, Developments to date," <u>Drugs Aging</u> , 19(7): 487-494 (2002).	<input type="checkbox"/>	
	168	WAKABAYASHI et al., "α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy," <u>Neuroscience Letters</u> , 249:180-182 (1998).	<input type="checkbox"/>	
	169	WAKABAYASHI et al., "NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease," <u>Neuroscience Letters</u> , 239(1) 45-48 (1997).	<input type="checkbox"/>	
	170	WAKABAYASHI et al., "Widespread occurrence of α-synuclein/NCAP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies," <u>Neuropathology and Applied Neurobiology</u> , 25(5): 363-368 (1999).	<input type="checkbox"/>	
	171	WAKABAYASHI et al., "Accumulation of α-synuclein/NCAP is a cytopathological feature common to Lewy body disease and multiple system atrophy," <u>Acta Neuropathol.</u> , 96(5): 445-452 (1998).	<input type="checkbox"/>	
	172	WALKER et al., "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," <u>J. Neuropath. Exp. Neurology</u> , 53(4):377-383 (1994).	<input type="checkbox"/>	
	173	WATSON et al., "Chapter 14: The Introduction of Foreign Genes into Mice," <u>Molecular Biology of Watson Recombinant DNAs</u> , 2nd ed., 255-272 (1993).	<input type="checkbox"/>	
	174	WEINREB et al., "NACP, A Protein Implicated in Alzheimer's Disease and Learning, Is Natively Unfolded," <u>Biochemistry</u> , 35(43):13709-13715 (1996).	<input type="checkbox"/>	
	175	WISNIEWSKI et al., "Therapeutics in Alzheimer's and Prion Diseases," <u>Biochemical Society Transactions</u> , 30(4):574-587 (2002).	<input type="checkbox"/>	
Examiner Signature				Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/699,517
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Steven H. Standley
Sheet	13	of	13	Attorney Docket Number	015270-008920US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	210	WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," <u>PNAS</u> , 82:8729-8732 (1985).	<input type="checkbox"/>
	176	YOSHIMOTO et al., "NACP, the precursor protein of the non-amyloid β /A4 protein (A β) component of Alzheimer disease amyloid, binds A β and stimulates A β aggregation," <u>PNAS</u> , 92:9141-9145 (1995).	<input type="checkbox"/>
	211	ZHOU et al., "A Human Single-Chain Fv Intrabody Blocks Aberrant Cellular Effects of Overexpressed alpha-Synuclein," <u>Mol Ther.</u> , 10(6):1023-31 (2004).	<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.